NCT02321540 2023-10-25
A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
3 trialsNCT02403271 2019-01-03
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02950038 2017-02-13
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn